KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.

Abstract

Background:

Uveal Melanoma (UM) is a potentially lethal cancer, and epigenetics may participate in the regulation of MEK resistance. This study is aimed at targeting the epigenetic kinase to overcome the resistance to MEK inhibitor.

Method:

We developed the 92.1 and OMM1 MEK-inhibitor resistant cell lines by culturing them in the trametinib (Tra) mixed medium. We utilized CCK8 analysis for detecting the viability of the cell. Western blot was used to determine the ERK1/2 and Akt phosphorylation. Small compound library screening assays were carried out by CCK8 analysis. To test the apoptosis, we employed flow cytometric analysis with Annexin-V/PI. Western blot and CCK8 were used to explore the epigenetic regulation of KDM5B in MEK-resistance cell lines. To knock out the expression level of KDM5B, we used the CRISPR/Cas9 by lentivirus delivering well-validated shRNAs in pLKO.1 vector. The directly binding affinity of KDOAM-25 to KDM5B was determined by drug affinity responsive target stability (DARTS) and microscale thermophoresis (MST).

Results:

The phosphorylation of ERK1/2 and Akt (T308) was inhibited in OMM1 cell lines. However, inhibition of Tra was abolished in OMM1-R cell lines. From a compound screening assay, we identified that KDOAM-25 robustly inhibited the viability and colony formation of MEK-resistance cell lines. Furthermore, KDOAM-25 significantly promoted cell death in OMM1-R cells. H3K4me3 (tri-methylation of lysine 4 on histone H3) and H3K27ac (acetyl of lysine 27 on histone H3) were both upregulated in OMM1-R cells. Tra significantly inhibited the expression of KDM5B in OMM1-P cells. However, the effect on KDM5B was abolished in OMM1-R cells. Knockdown of KDM5B robustly suppressed the cell viability in OMM1-R cells. KDOAM-25 directly interacted with KDM5B.

Conclusion:

KDOAM-25 inhibited the viability and colony formation and promoted cell death of MEK-resistance cell lines through H3K4me3 and H3K27ac, indicating that KDOAM-25 may be a potential therapeutic agent for MEK resistance in UM patients.

• Authors: Hongjun Zhang, Xiangnan Liu, Yong'an Chen, Rui Xu, Shengli He
• Journal: BioMed research international (Biomed Res Int) Vol. 2022 Pg. 1556485 ( 2022) ISSN: 2314-6141 [Electronic] United States
• PMID: 36212716 (Publication Type: Journal Article, Retracted Publication)
• Copyright: Copyright © 2022 Hongjun Zhang et al.

Chemical References

• Annexins
• Histones
• KDOAM-25
• Nuclear Proteins
• Protein Kinase Inhibitors
• Repressor Proteins
• Niacinamide
• Jumonji Domain-Containing Histone Demethylases
• KDM5B protein, human
• Proto-Oncogene Proteins c-akt
• Mitogen-Activated Protein Kinase Kinases
• Lysine
• Glycine

Topics

• Annexins
• Cell Line, Tumor
• Cell Proliferation
• Epigenesis, Genetic
• Glycine (analogs & derivatives)
• Histones (metabolism)
• Humans
• Jumonji Domain-Containing Histone Demethylases (genetics, metabolism)
• Lysine (metabolism)
• Melanoma
• Mitogen-Activated Protein Kinase Kinases (metabolism)
• Niacinamide (analogs & derivatives)
• Nuclear Proteins (metabolism)
• Protein Kinase Inhibitors (pharmacology)
• Proto-Oncogene Proteins c-akt (metabolism)
• Repressor Proteins (metabolism)
• Uveal Neoplasms